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T he definition of osteoporosis by the World Health Organization (WHO) is based on the T-score cri-
teria applied to bone mineral density (BMD) by 
dual-energy X-ray absorptiometry (DXA) measure-
ments at the femoral neck and lumbar spine [1].  
Osteoporosis is a disease that can increase the risk of 
fracture due to low bone mineral density (BMD) [2].  
Bone fracture is further associated with an increase in 
mortality in the elderly [3] and is also one of the major 
reasons for the hospitalization of elderly individuals [4].  
According to the Ministry of Health,  Labour and 
Welfare of Japan,  healthcare costs have escalated over 
the past few decades along with the super-aging of 
Japanese society,  creating a major problem for main-
taining the country’s universal health insurance cover-
age.  Approximately 60% of the total national medical 
care expenditure is for people > 65 years of age.  The 
number of bone fractures in elderly patients has been 
increasing [4],  and there are approximately 13 million 
osteoporosis patients in Japan [5].  The increase in bone 
fractures has also resulted in an increase in medical 
expenses for elderly people [6].  In order to reduce the 
incidence of bone fractures,  efforts should be made to 
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Osteoporosis increases the risk of bone fractures.  It is diagnosed based on an individual’s bone mineral density 
(BMD) or a fracture without trauma.  BMD is usually measured by the dual energy X-ray absorptiometry 
(DXA) method.  Here we investigated factors for the earliest possible prediction of decreased BMD by examin-
ing the relationships between patients’ BMD values and changes in the patients’ physical and laboratory values.  
We retrospectively reviewed the medical records of 149 patients who visited our department in 2014-2015 for a 
variety of reasons and underwent an area BMD examination by DXA.  We analyzed the relationships between 
decreasing BMD and the patients’ gender,  age,  body mass index (BMI),  medical background,  hemoglobin,  
electrolytes,  and thyroid function.  Thirty-nine of the patients were diagnosed with osteoporosis based on their 
T-scores.  An adjusted analysis showed that female gender,  aging,  and increased serum calcium level were sig-
nificantly related to decreasing femoral BMD,  whereas high BMI was associated with an increase in femoral 
BMD.  Collectively the results indicate that for the early detection of low BMD,  it is important for gener-
al-practice physicians to consider conducting a BMD checkup when treating female and elderly patients with a 
low BMI and/or elevated serum calcium level.
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reduce the number of osteoporosis patients with low 
BMD.
Historically,  the participation rate in osteoporosis 
examinations has been very low in Japan.  For this rea-
son,  physicians should always consider whether 
patients visiting a clinic for any reason might also 
require an osteoporotic checkup for the detection of low 
BMD.  In the present study,  to establish a clinical hall-
mark for predicting low BMD in a variety of patients,  
we retrospectively analyzed the relationships between 
low BMD and various factors,  including gender,  body 
mass index (BMI),  key laboratory data,  treatments,  
and complicated diseases.
Patients and Methods
Study subjects. A total of 2,593 patients visited 
the Department of General Medicine,  Okayama 
University Hospital during the period from January 
2014 to December 2015.  We retrospectively reviewed 
the medical records of 168 patients who visited the 
department and underwent a BMD examination during 
that period.  Seven patients with missing body weight 
and height data were excluded.  Twelve patients for 
whom the basic data of blood examination such as white 
blood cell count were lacking were also excluded.  The 
data of a final total of 149 patients were analyzed 
(Fig. 1).  The patients included 53 males (35.6%) and 96 
females (64.4%),  and the mean age of the patients was 
58.58 years (range 19-87 years) (Table 1).  As shown in 
Table 2,  we categorized the patients into 6 groups 
according to their primary disorders: (1) endocrine- 
metabolic disorders (Endocrine),  (2) infections and 
inflammatory diseases (Infection),  (3) neoplastic dis-
eases (Neoplasm),  (4) autoimmune-collagen disorders 
(Autoimmune),  (5) anorexia and malnutrition 
(Anorexia),  and (6) Others.  We also divided all of the 
subjects into three groups by T-scores defined by WHO 
as follows: (1) normal range of femoral BMD (T-score 
≥ −1),  (2) low femoral BMD (−2.5 < T-score < −1),  and 
(3) osteoporosis (T-score ≤ −2.5).  Table 3 shows the 
numbers and ratios of patients classified by the disease 
categories in the three BMD-divided subgroups of nor-
mal BMD,  low BMD,  and osteoporosis.  The study 
protocol was approved by the Okayama University 
Graduate School of Medicine,  Dentistry and 
Pharmaceutical Sciences and the Okayama University 
Hospital Ethics Committee (approval no. K1606-014).
Definition of bone strength,  and laboratory and 
clinical examinations. We used a DXA system called 
the Horizon-type A (140/100 kVp,  2.5 mA,  82 sec;  
Hologic,  Marlborough,  MA,  USA) at Okayama 
University Hospital.  The area BMD measured by DXA 
is expressed as grams of mineral per square centimeter 
scanned (g/cm2).  Since the lumbar BMD in elderly 
patients is greatly affected by the presence of osteo-
phytes,  we used the femoral BMD values in this study.  
The T-score is a comparison of a patient’s BMD to that 
of healthy young adults.  Information on the patients’ 
past medical history,  clinical background,  and treat-
ments was obtained from their medical records.
Since iron-deficiency anemia [7],  hyponatremia [8],  
loss of serum calcium and inorganic phosphorus [9],  
and complication of thyroid diseases [10] are known to 
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Table 1　 Patientsʼ characteristics (continuous variables)
Mean SD Number
Age (year) 58.58 16.74 149
BMD (g/cm2) Femoral BMD 0.62 0.14 149
Femoral T-score -1.71 1.15
BMI (kg/m2) 22.72 5.63 149
Laboratory data Hb (g/dL) 12.47 2.22 149
Na (mEq/L) 138.73 3.57 147
Ca (mg/dL) 9.48 0.66 131
IP (mg/dL) 3.44 0.88 119
FT4 (ng/dL) 1.15 0.25 84
BMD,  bone mineral density; BMI,  body mass index; Hb,  hemoglo-
bin; Na,  sodium; Ca,  calcium; IP,  inorganic phosphorus; FT4,  
free thyroxine; SD,  standard deviation.
Excluded:
Missing of laboratory data
(n=12)
Excluded:
Missing of physical data
(n=7)
Patients for analysis
(n=161)
Patients included for 
analysis (n=149)
Patients in whom BMD 
was examined by the 
DXA method (n=168) 
Fig. 1　 Study participants.  Bone mineral density (BMD) was 
measured in 168 patients.  Seven patients were excluded because 
of missing physical data,  and 12 patients were excluded because 
of missing laboratory data.  The data of 149 patients were analyzed.
be associated with osteoporosis,  we analyzed each 
patient’s blood examination data including those for 
hemoglobin (Hb),  sodium (Na),  calcium (Ca),  inor-
ganic phosphorus (IP) and free thyroxine (FT4),  which 
were determined by an auto-analyzer system at the 
Central Laboratory of Okayama University Hospital.  
The use of heparin or warfarin [11],  proton-pump 
inhibitors (PPIs) [12],  antihypertensive drugs including 
angiotensin-receptor blockers [13] and loop diuretics 
[14],  thiazolidinedione [15],  benzodiazepine [16],  and 
some psychiatric drugs such as anxiolytics,  sedatives,  
and neuroleptics [17] have been reported to be associ-
ated with the risk of bone fractures.  Taking glucocorti-
coids is also a potential risk factor for the development 
of osteoporosis [18].
Anti-diabetic DPP-4 inhibitors [19] and anti-dyslip-
idemic statins [20] seem to have some beneficial effect 
on BMD.  Considering the effects of these drugs on 
bone metabolism,  we classified the drugs administered 
to the patients into the following 8 groups: (1) antihy-
pertensive drugs,  (2) loop diuretics,  (3) antidiabetic 
drugs,  (4) antipsychotic/sleeping drugs,  (5) anticoagu-
lants/antiplatelet drugs,  (6) statins,  (7) proton pump 
inhibitors,  and (8) glucocorticoids.
Statistical analyses. The normally distributed 
continuous variables are presented as the mean and 
standard deviation (SD),  and the non-normally distrib-
uted continuous variables are presented as the median 
and interquartile range.  Categorical variables are 
described using proportional distributions.  To estimate 
the effect of each variable,  we performed linear regres-
sion analyses using femoral BMD as a dependent vari-
able and the other variables as explanatory variables 
(crude analysis),  yielding unstandardized regression 
coefficients (coeff.) and their 95% confidence intervals 
(CIs).  To adjust for potential confounding,  we used an 
adjusted model that included all variables (adjusted 
analysis).  Some of the missing data (Na,  Ca,  IP,  and 
FT4) were handled through multiple imputation by pre-
dictive mean matching [21].
We created a total of 40 imputed datasets by explan-
atory variables without missing values for the analysis.  
Values were missing for the following items: FT4 alone 
in 42 cases,  IP and FT4 in 14 cases; Ca,  IP and FT4 in 
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Table 2　 Patientsʼ characteristics (categorious variables)
% Number
Gender Female 64.4 96
Male 35.6 53
Total 100.0 149
Main disease Endocrine-Metabolic disorders 45.0 67
Infections and inﬂammatory diseases 14.1 21
Neoplastic diseases 14.1 21
Autoimmune-Collagen disorders 11.4 17
Anorexia and Malnutrition 6.7 10
Others 8.7 13
Total 100.0 149
Drugs Proton pump inhibitors 27.5 41
Antihypertensive drugs 26.2 39
Antipsychotic/sleeping drugs 20.8 31
Statins 20.8 31
Antidiabetic drugs 12.8 19
Glucocorticoids 11.4 17
Anticoagulants/antiplatelet drugs 11.4 17
Loop diuretics 6.0 9
Total 136.9＊ 204＊
＊There might be duplicate taking.  The patients were categorized into 6 groups according to their main disease: 1) Endocrine-Metabolic 
disorders (Endocrine),  2) Infections and inﬂammatory diseases (Infection),  3) Neoplastic diseases (Neoplasm),  4) Autoimmune-Collagen 
disorders (Autoimmne),  5),  Anorexia and Malnutrition (Anorexia),  and 6) others.
8 cases; Ca alone in 6 cases; IP alone in 5 cases; Ca 
and IP in 2 cases; Na,  Ca and IP in 1 case; Na alone in 
1 case; and Ca and FT4 in 1 case.
All statistical analyses were performed using Stata/
MP4 ver. 15.1 (Stata Corp.,  College Station,  TX).  All 
p-values were two-sided,  and p-values < 0.05 were 
accepted as significant [21].
Results
Patient characteristics of BMD,  laboratory data 
and basal disorders. We analyzed the clinical data of 
patients who visited our department with various com-
plaints.  The age distributions of the patients are 
graphed for each gender in Fig. 2.  Osteoporosis was 
identified in 39 (26.2%) of the 149 patients.  The pro-
portions of male and female osteoporotic patients were 
12.8% and 87.2%,  respectively.  Our analyses revealed 
that the following factors in the patient profiles and 
physical and laboratory data were closely linked to a 
decrease in femoral BMD: female gender,  advanced 
age,  high BMI,  and high serum calcium level.  We thus 
consider these factors to be important for detecting 
osteoporosis at an early stage.
The patients’ characteristics are summarized in 
Table 1.  The mean±SD of femoral BMD was 
0.62 ± 0.14 g/cm2.  The patients’ laboratory data,  
including Hb and serum levels of Na,  Ca,  IP and FT4,  
were almost all within normal ranges (Table 1).  The 
numbers of patients in the disease categories were as 
follows: Endocrine (67 patients,  45.0%),  Neoplasm 
(21,  14.1%),  Infection (21,  14.1%),  Autoimmune (17,  
11.4%),  Anorexia (10,  6.7%),  and Others (13,  8.7%).  
The percentage of patients with endocrine-metabolic 
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Table 3　 Femoral T-score levels and disease category
Femoral T-score levels
Normal Low BMD Osteoporosis
T-score≧-1 -2.5＜T＜-1 T≦-2.5
Number % Number % Number %
All patients
　Endocrine-Metabolic disorders 21 51.2 33 47.8 13 33.3
　Infections and inﬂammatory diseases 5 12.2 11 15.9 5 12.8
　Neoplastic diseases 3 7.3 10 14.5 8 20.5
　Autoimmune-Collagen disorders 6 14.6 6 8.7 5 12.8
　Anorexia and Malnutrition 2 4.9 4 5.8 4 10.3
　Others 4 9.8 5 7.2 4 10.3
Total 41/149 100 69/149 100 39/149 100
Male only
　Endocrine-Metabolic disorders 12 57.1 7 25.9 3 60
　Infections and inﬂammatory diseases 2 9.5 5 18.5 0 0
　Neoplastic diseases 3 14.3 7 25.9 1 20
　Autoimmune-Collagen disorders 3 14.3 2 7.4 1 20
　Anorexia and Malnutrition 0 0 1 3.7 0 0
　Others 1 4.8 5 18.5 0 0
Total 21/149 100 27/149 100 5/149 100
Female only
　Endocrine-Metabolic disorders 9 45 26 61.9 10 29.4
　Infections and inﬂammatory diseases 3 15 6 14.3 5 14.7
　Neoplastic diseases 0 0 3 7.1 7 20.6
　Autoimmune-Collagen disorders 3 15 4 9.5 4 11.8
　Anorexia and Malnutrition 2 10 3 7.1 4 11.8
　Others 3 15 0 0 4 11.8
Total 20/149 100 42/149 100 34/149 100
Normal T-score≧-1,  Low BMD -2.5＜T＜-1,  Osteoporosis T≦-2.5.
disorders (45.0%) was highest.
The drugs administered for individual treatments are 
shown in Table 2.  The numbers of patients in the 
drug-categorized groups were as follows: PPIs (41 
patients,  27.5%),  antihypertensive drugs (39,  26.2%),  
antipsychotic/sleeping drugs (31,  20.8%),  statins (31,  
20.8%),  antidiabetic drugs (19,  12.8%),  glucocorti-
coids (17,  11.4%),  anticoagulants/antiplatelet drugs 
(17,  11.4%),  and loop diuretics (9,  6.0%).  The per-
centage of patients who were administered a PPI 
(27.5%) was the highest.
Characteristics categorized by femoral BMD levels.
As shown in Table 3,  the number of patients with 
endocrine-metabolic diseases was the largest among the 
three gender-divided subgroups.  Table 3 also shows the 
numbers and ratios of male patients classified by disease 
categories.  In the osteoporosis group,  only 5 of 39 
patients were male.  In the male osteoporosis sub-
groups,  there were only three disease categories: En-
docrine,  Autoimmune,  and Neoplasm.  In contrast,  
there were 34 female patients with osteoporosis,  among 
whom disorders in all 6 categories were present (Table 
3).
Multiple regression analysis for factors that affect 
BMD. Table 4 shows the results of the liner regres-
sion analysis based on the patients’ femoral BMD levels.  
The adjusted analysis revealed that female gender 
(coeff. = −0.129,  95%CI [−0.171,  −0.088],  p < 0.0001) 
was significantly associated with decreasing femoral 
BMD compared to male gender (Table 4).  We also 
observed that the effect of aging,  based on 10-year 
increments (coeff. = −0.033,  95%CI: −0.046 to −0.019,  
p < 0.001) was related to a decrease in femoral BMD.
Of note,  higher BMI levels (coeff. = 0.005,  95%CI:  
0.002-0.009,  p = 0.005) were significantly linked to an 
increase in femoral BMD (Table 4).  Increased serum 
corrected calcium levels (coeff. = −0.042,  95%CI:  
−0.073 to −0.012,  p = 0.007) were significantly associ-
ated with a decrease in femoral BMD.  In the crude 
analysis,  only anorexia and malnutrition (coeff. =−0.115,  
95%CI: −0.209 to −0.021,  p = 0.017) were significantly 
related to low femoral BMD among the disease groups.  
Among the medications,  the use of a PPI (coeff. =−0.063,  
95%CI: −0.114 to −0.013,  p = 0.014) was significantly 
associated with decreasing femoral BMD,  though these 
trends were not detected in the adjusted analysis.
Since the average of the VIF statistics was 1.43 in the 
multiple regression analysis,  multiple co-linearity was 
not shown.  A plot of multiple liner regression analysis 
for factors affecting the femoral BMD levels is shown in 
Fig. 3,  which illustrates the relationships between BMD 
and female gender,  age,  BMI,  and serum calcium 
based on an adjusted analysis of the multiple liner 
regression analysis results (Table 4).
Discussion
We analyzed clinical data including BMD and labo-
ratory data for 149 patients who visited our department 
during a 2-year period.  Our analyses clarified that (1) 
female gender was significantly associated with decreas-
ing femoral BMD compared to male gender,  and (2) 
increased serum calcium level,  (3) aging,  and (4) low 
BMI were significantly linked to a decrease in femoral 
BMD.
The difference in the numbers of female and male 
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Female
Number
y/o0
5
10
15
20
25
30
35
40
45
50
＜20 ＜40 ＜60 ＜80 80≦
Male
Number
y/o0
5
10
15
20
25
＜20 ＜40 ＜60 ＜80 80≦
Fig. 2　 Age distribution in each gender of the study population.  The age distribution of female patients was skewed toward the meno-
pausal condition,  with 62 (64.5%) of the 96 women aged ＞55 years.
osteoporotic patients indicates the possibility that 
female gender itself is a critical factor for BMD com-
pared to other clinical factors.  Our adjusted model 
revealed that female gender was significantly associated 
with decreasing femoral BMD compared to male gen-
der.  Regarding female gender,  menopause,  the natural 
age of which ranges from 50 to 55 years,  is generally 
linked to a decrease of femoral BMD [22].  Since the age 
distribution of the female patients in our cohort was 
skewed to the menopausal condition (62 of the 96 
women [64.5%] were aged > 55 years),  it was difficult to 
analyze the data by dividing the women into 2 groups of 
pre- and post-menopausal conditions.  However,  
female gender and aging are likely to be independently 
related to lowered BMD [23 , 24].  It has also been 
reported that men showed higher BMD values than 
women at the same age [25],  suggesting that female sex 
hormones could be critical for the gender-dependent 
difference of BMD regardless of menopause.  Further 
prospective studies are needed to clarify the inter-rela-
tionships among gender difference,  changes of sex ste-
roids,  and the existence of menopause.
We also observed that aging was significantly cor-
related with a decrease in femoral BMD regardless of 
gender.  The decrease in BMD caused by aging is related 
to the acceleration of bone remodeling [26 , 27],  an 
increase in oxidative stress [28],  and decreases in cal-
cium absorption [29] and secondary bone calcification 
[30].  Although we did not retrospectively analyze these 
factors in the present study,  a BMD examination should 
be recommended for women aged ≥ 50 years consider-
ing the decline in estrogen in females.  It has also been 
reported that most fractures in elderly people are at 
cortical sites [31],  indicating the difficulty in determin-
ing the risk of bone fractures in elderly people.
A gain in BMI also had a significant relation to 
increasing femoral BMD in our study.  It is possible that 
the BMI is more strongly correlated with BMD regard-
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Table 4　 Results of multiple regression analysis with femoral BMD as outcome
Crude analysis Adjusted analysis
Coef. 95%CI p-value Coef. 95%CI p-value
Gender Male 0.000 Reference 0.000 Reference
Female -0.135 -0.178 -0.093 ＜0.001＊＊ -0.129 -0.171 -0.088 ＜0.001＊＊
MD Endocrine-Metabolic disorders 0.000 Reference 0.000 Reference
Autoimmune-Collagen disorders -0.025 -0.100 0.050 0.515 0.022 -0.048 0.092 0.537
Neoplastic diseases -0.052 -0.122 0.017 0.137 -0.027 -0.102 0.047 0.470
Infections and inﬂammatory diseases -0.032 -0.101 0.038 0.368 0.018 -0.048 0.084 0.588
Anorexia and Malnutrition -0.115 -0.209 -0.021 0.017＊ -0.085 -0.173 0.002 0.056
Others -0.027 -0.111 0.057 0.531 0.002 -0.067 0.071 0.956
Age (10-year increments) -0.029 -0.042 -0.016 ＜0.001＊＊ -0.033 -0.046 -0.019 ＜0.001＊＊
BMI 0.008 0.004 0.012 ＜0.001＊＊ 0.005 0.002 0.009 0.005＊＊
Drugs Antihypertensive drugs -0.018 -0.070 0.034 0.495 0.028 -0.019 0.075 0.240
Loop diuretics -0.014 -0.110 0.083 0.782 -0.056 -0.137 0.026 0.178
Antidiabetic drugs 0.029 -0.039 0.098 0.398 0.011 -0.049 0.071 0.713
Antipsychotic/sleeping drugs -0.055 -0.111 0.001 0.052 -0.045 -0.093 0.003 0.067
Anticoagulants/antiplatelet drugs 0.030 -0.042 0.102 0.405 0.044 -0.019 0.107 0.170
Statins 0.004 -0.053 0.060 0.894 -0.010 -0.060 0.040 0.698
Proton pump inhibitors -0.063 -0.114 -0.013 0.014＊ -0.049 -0.101 0.004 0.069
Glucocorticoids 0.047 -0.025 0.118 0.201 0.031 -0.034 0.095 0.353
Labo Hb 0.009 -0.001 0.019 0.083 -0.011 -0.021 0.000 0.053
Na 0.001 -0.006 0.007 0.807 0.000 -0.006 0.006 0.925
Corrected Ca -0.022 -0.057 0.014 0.234 -0.042 -0.073 -0.012 0.007＊＊
IP 0.015 -0.015 0.045 0.316 0.019 -0.006 0.043 0.141
FT4 -0.016 -0.126 0.094 0.772 -0.028 -0.118 0.061 0.531
Abbreviations: see footnotes of Table 1 and Table 2.  MD,  Main disease; Labo,  Laboratory data.  ＊p＜0.05 and ＊＊p＜0.01.
less of age or gender [32].  In this regard,  reduced BMI 
in the elderly may be linked to frailty,  which is defined 
as a clinical state with increased vulnerability resulting 
from an aging-related decline in physiologic functions 
involving various organs in the elderly [33].  Frailty is a 
syndrome including key phenotypic conditions such as 
weakness,  slower walking speed,  lower physical activity 
and energy,  exhaustion,  and unintentional weight loss 
[33].  Since a low BMI or weight loss in the elderly is an 
important component of frailty,  attention should be 
given to the risk of lowered BMI in lean elderly people 
in order to avoid the development of osteoporosis.
Regarding the serum calcium level,  it is generally 
recognized that the major causes of hypercalcemia are 
primary hyperparathyroidism and malignancy [34].  In 
our adjusted analysis,  hypercalcemia was found to be 
significantly correlated with decreasing BMD inde-
pendently of other factors,  whereas the serum level of 
inorganic phosphate was not directly associated with 
BMD.  There were 26 patients with hypercalcemia with 
a serum calcium level > 10 mg/dL,  including 16 female 
patients (61.5%) and 25 patients with a low BMI (≤ 20) 
(96.2%).  Because of these factors,  the relationship 
between hypercalcemia and decreasing femoral BMD 
seemed to be underestimated in our crude analysis.  The 
adjusted analysis enabled a correct estimation of the 
relationship between hypercalcemia and decreasing 
femoral BMD.  Since patients with elevated serum cal-
cium are likely to become osteoporotic within approxi-
mately 10 years [35],  hypercalcemic patients should be 
monitored in order to determine the causes of calcium 
dysregulation and to prevent the progression of osteo-
porosis.
In our patient cohort,  other clinical factors did not 
directly affect decreasing BMD,  including autoimmune 
diseases,  anorexia and malnutrition,  and the intake of 
glucocorticoids and PPIs,  which would be expected to 
be involved in low BMD.  These discrepancies might be 
due to the small numbers of our patients with these dis-
orders.  For example,  among the 17 patients with auto-
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Gender
Main disease
Drugs
Laboratory
data
＊＊
＊＊
＊＊
＊＊
Associated with decreasing BMD Associated with increasing BMD
-0.225 -0.175 -0.125 -0.075 -0.025 0.025 0.075 0.125
Male
Endocrine-Metabolic disorders
Age (10-year increments)
Neoplastic diseases
Anorexia and Malnutrition
Others
Antihypertensive drugs
BMI
Antidiabetic drugs
Statins
Proton pump inhibitors
Glucocorticoids
Serum Na
Serum Ca
Serum IP
Hemoglobin
Female
Anticoagulants/antiplatelet drugs
Serum FT4
Loop diuretics
Infections and inﬂammatory diseases
Autoimmune-Collagen disorders
Antipsychotic/sleeping drugs
Fig. 3　 Inter-relationships between clinical factors and femoral BMD.  A plot of the multiple liner regression analysis results for factors 
that aﬀect femoral BMD (see Table 4) is shown.  The relationships between BMD and the factors of female gender,  age,  BMI,  and serum 
Ca were signiﬁcant.  Na,  sodium; Ca,  calcium; IP,  inorganic phosphorus; FT4,  serum free thyroxine.  ＊＊p＜0.05.
immune-collagen disorders,  only 4 had rheumatoid 
arthritis.  Only 10 of the 149 patients had anorexia or 
malnutrition.  Seventeen patients were taking glucocor-
ticoids,  which are known to cause osteoporosis [36 , 37],  
and only 6 of those patients had been administered 
glucocorticoids for > 1 year.  Thirty-three (80.5%) of the 
patients taking a PPI were > 60 years old.  These devia-
tions in the patient numbers and distribution of ages 
and/or gender might have played a role in the unex-
pected results obtained in this study.
In addition,  DXA measurements at the hip and 
spine are common and useful methods for diagnosing 
osteoporosis in daily medical practice [38]; however,  
high-resolution peripheral quantitative computed 
tomography (HRpQCT) was recently introduced to 
measure volumetric BMD and micro-architectural bone 
fractures [39].  In a future study,  HRpQCT would be 
more advantageous for assessing cortical porosity [40].
Collectively,  our present findings revealed that,  in 
clinical practice for general medicine,  female gender 
and aging factors are important to predict a decrease in 
femoral BMD.  Attention should also be paid to the 
possibility of low BMD in patients with a high serum 
calcium level and/or low BMI.  There were two main 
limitations in this study.  First,  this was a retrospective 
analysis.  Approximately 95% of the patients who visited 
our department in 2014-2015 did not undergo a DXA 
examination,  suggesting that risk factors for decreasing 
BMD might be underestimated in unexamined patients 
by attending physicians.  Another study limitation is 
that the percentage of patients with endocrine diseases 
was higher than the percentages of patients with other 
diseases.  Nevertheless,  to prevent fractures in such 
patients,  we should always pay attention to key clinical 
factors considering the possibility of decreasing BMD 
among individuals who visit a general medical practice.
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